Although genomic alterations in ErbB genes are uncommon in prostate cancer, emerging evidence suggests ErbB signaling serves an important role in advanced-stage disease, and targeting these receptors may have therapeutic potential (11–16). This evidence concerns the gene EGFR and prostate cancer.